Abstract: The Pharmacopoeia of the People’s Republic of China(ChP) 2025 Edition was officially released in March 2025 and implemented on October 1, 2025. The standard system of this new-edition pharmacopoeia is more refined, the quality of pharmaceuticals is more controllable, and its alignment with international standards is further enhanced. As a result, the overall level of national pharmaceutical standards has stepped onto a new stage. To facilitate the dissemination and application of the ChP 2025 Edition, and to guide drug control institutions, enterprises, and departments involved in drug research and development, production, distribution, and supervision to quickly adapt to its new requirements, this issue launches the special column “Interpretation and Application of the Chinese Pharmacopoeia 2025 Edition.” This column provides in-depth analysis of the revision background, technical key points, and implementation prospects of core standards across various fields. It aims to serve as a systematic and practical technical reference for the industry to accurately understand and effectively implement the new pharmacopoeia, thereby ensuring public medication safety and promoting the high-quality development of the pharmaceutical industry.